Enveric Biosciences (ENVB) Competitors $0.32 0.00 (-1.04%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ENVB vs. ACXP, CARA, HCWB, TXMD, MRNS, SLGL, CING, IPA, NRSN, and IMNNShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Acurx Pharmaceuticals (ACXP), Cara Therapeutics (CARA), HCW Biologics (HCWB), TherapeuticsMD (TXMD), Marinus Pharmaceuticals (MRNS), Sol-Gel Technologies (SLGL), Cingulate (CING), ImmunoPrecise Antibodies (IPA), NeuroSense Therapeutics (NRSN), and Imunon (IMNN). These companies are all part of the "pharmaceutical preparations" industry. Enveric Biosciences vs. Acurx Pharmaceuticals Cara Therapeutics HCW Biologics TherapeuticsMD Marinus Pharmaceuticals Sol-Gel Technologies Cingulate ImmunoPrecise Antibodies NeuroSense Therapeutics Imunon Enveric Biosciences (NASDAQ:ENVB) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Do analysts prefer ENVB or ACXP? Enveric Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 2,976.92%. Acurx Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 1,354.55%. Given Enveric Biosciences' higher probable upside, equities analysts plainly believe Enveric Biosciences is more favorable than Acurx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ENVB or ACXP? Acurx Pharmaceuticals received 9 more outperform votes than Enveric Biosciences when rated by MarketBeat users. Likewise, 93.33% of users gave Acurx Pharmaceuticals an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote. CompanyUnderperformOutperformEnveric BiosciencesOutperform Votes555.56% Underperform Votes444.44% Acurx PharmaceuticalsOutperform Votes1493.33% Underperform Votes16.67% Is ENVB or ACXP more profitable? Enveric Biosciences' return on equity of -221.54% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enveric BiosciencesN/A -221.54% -164.32% Acurx Pharmaceuticals N/A -392.36%-223.78% Which has stronger valuation and earnings, ENVB or ACXP? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnveric BiosciencesN/AN/A-$17.29M-$2.56-0.13Acurx PharmaceuticalsN/AN/A-$14.58M-$1.09-0.76 Do institutionals & insiders have more ownership in ENVB or ACXP? 13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 1.2% of Enveric Biosciences shares are held by company insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer ENVB or ACXP? In the previous week, Enveric Biosciences' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score. Company Overall Sentiment Enveric Biosciences Neutral Acurx Pharmaceuticals Neutral Which has more risk and volatility, ENVB or ACXP? Enveric Biosciences has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.86, meaning that its stock price is 286% less volatile than the S&P 500. SummaryEnveric Biosciences beats Acurx Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Ad Stansberry Research$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.31M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.1310.5990.1317.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.465.094.784.78Net Income-$17.29M$151.83M$120.31M$225.60M7 Day Performance-10.59%-2.14%-1.92%-1.23%1 Month Performance-2.49%-4.56%13.65%0.46%1 Year Performance-75.38%8.87%28.34%15.24% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.5233 of 5 stars$0.33-1.0%$10.00+2,976.9%-75.9%$3.31MN/A-0.137Gap DownACXPAcurx Pharmaceuticals1.3843 of 5 stars$0.83-2.4%$12.00+1,338.0%-77.0%$14.10MN/A-0.783Gap UpCARACara Therapeutics4.2299 of 5 stars$0.25-4.2%$2.32+824.3%-29.0%$13.77M$8.69M-0.1555News CoverageGap DownHCWBHCW Biologics0.406 of 5 stars$0.36-0.3%N/A-60.4%$13.46M$3.50M-0.3640Gap DownTXMDTherapeuticsMD0.4374 of 5 stars$1.15-5.7%N/A-53.8%$13.26M$1.30M0.00420Analyst ForecastGap UpHigh Trading VolumeMRNSMarinus Pharmaceuticals4.3176 of 5 stars$0.24-10.2%$4.79+1,927.8%-97.6%$13.02M$31.47M-0.10110Analyst ForecastNews CoverageSLGLSol-Gel Technologies2.4245 of 5 stars$0.46-3.5%$5.00+981.1%-66.5%$12.89M$1.55M-1.3650CINGCingulate2.2233 of 5 stars$4.00-5.0%$8.00+100.0%+100.0%$12.85MN/A0.0013IPAImmunoPrecise Antibodies2.9227 of 5 stars$0.43+5.4%$5.00+1,076.5%-69.5%$12.25M$24.07M-0.5280News CoverageNRSNNeuroSense Therapeutics0.4862 of 5 stars$0.89+3.2%N/A+75.0%$12.12MN/A-0.9518Earnings ReportGap DownIMNNImunon2.3546 of 5 stars$0.84-1.1%$20.50+2,354.2%+9.2%$12.11M$500,000.00-0.4533Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies ACXP Alternatives CARA Alternatives HCWB Alternatives TXMD Alternatives MRNS Alternatives SLGL Alternatives CING Alternatives IPA Alternatives NRSN Alternatives IMNN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENVB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENVB Stock Alerts